Table 2.
Univariate and multivariate analyses for factors associated with overall survival of patients with intermediate to advanced HCC who received TACE with or without H101
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| PLT (vs. <100 × 109/L) | 1.467 (0.993–2.166) | 0.054 | NI | |
| ALT (vs. <40 U/L) | 1.267 (0.993–1.617) | 0.057 | NI | |
| AST (vs. <45 U/L) | 2.037 (1.568–2.646) | <0.001 | – | 0.228 |
| ALB (vs. <35 g/L) | 0.704 (0.512–0.968) | 0.031 | – | 0.424 |
| TBIL (vs. <20 mmol/L) | 1.213 (0.915–1.610) | 0.180 | NI | |
| IBIL (vs. <15 mmol/L) | 1.195 (0.809–1.765) | 0.372 | NI | |
| ALP (vs. <100 U/L) | 2.432 (1.859–3.180) | <0.001 | 1.494 (1.116–2.001) | 0.007 |
| CRP (vs. <8.2 mg/L) | 2.180 (1.722–2.759) | <0.001 | – | 0.102 |
| AFP (vs. <25 ng/mL) | 1.547 (1.200–1.994) | 0.001 | 1.389 (1.064–1.814) | 0.016 |
| HBsAg (vs. negative) | 0.658 (0.413–1.048) | 0.078 | NI | |
| HBV-DNA (vs. <100 IU/mL) | 1.104 (0.876–1.392) | 0.403 | NI | |
| NLR (vs. <3) | 1.477 (1.145–1.904) | 0.003 | – | 0.08 |
| Tumor size (vs. <5 cm) | 4.523 (3.156–6.481) | <0.001 | 3.120 (2.115–4.602) | <0.001 |
| Tumor number (vs. single) | 1.303 (1.019–1.668) | 0.035 | – | 0.409 |
| Splenomegaly (vs. no) | 1.179 (0.928–1.499) | 0.178 | NI | |
| Metastasis (vs. no) | 3.668 (2.377–5.662) | <0.001 | 2.111 (1.342–3.321) | 0.001 |
| Vascular invasion (vs. no) | 1.835 (1.443–2.335) | <0.001 | 1.292 (1.001–1.666) | 0.049 |
| Antiviral therapy (vs. no) | 0.752 (0.596–0.950) | 0.017 | – | 0.118 |
| TACE (vs. without H101) | 0.711 (0.563–0.896) | 0.004 | 0.623 (0.492–0.789) | <0.001 |
HR hazard ratio, CI confidence interval, NI not included. Other abbreviations as in Table 1
– Data not shown due to no significance